Does the media prefer IONS or AGIO?

In the previous week, Agios Pharmaceuticals had 2 more articles in the media than Ionis Pharmaceuticals. MarketBeat recorded 8 mentions for Agios Pharmaceuticals and 6 mentions for Ionis Pharmaceuticals. Ionis Pharmaceuticals' average media sentiment score of 0.47 beat Agios Pharmaceuticals' score of -0.01 indicating that Ionis Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ionis Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Agios Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to AGIO or ALKS?

In the previous week, Agios Pharmaceuticals had 4 more articles in the media than Alkermes. MarketBeat recorded 8 mentions for Agios Pharmaceuticals and 4 mentions for Alkermes. Alkermes' average media sentiment score of 0.35 beat Agios Pharmaceuticals' score of -0.01 indicating that Alkermes is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Agios Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Alkermes 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher valuation and earnings, GRAL or AGIO?

GRAIL has higher revenue and earnings than Agios Pharmaceuticals. GRAIL is trading at a lower price-to-earnings ratio than Agios Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio GRAIL $147.17M 42.60 -$408.35M -$9.75 N/A Agios Pharmaceuticals $54.03M 33.38 -$412.78M -$7.01 N/A

Does the media refer more to GRAL or AGIO?

In the previous week, GRAIL had 10 more articles in the media than Agios Pharmaceuticals. MarketBeat recorded 18 mentions for GRAIL and 8 mentions for Agios Pharmaceuticals. GRAIL's average media sentiment score of 0.46 beat Agios Pharmaceuticals' score of -0.01 indicating that GRAIL is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GRAIL 5 Very Positive mention(s) 4 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Agios Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor AGIO or IMVT?

In the previous week, Immunovant had 7 more articles in the media than Agios Pharmaceuticals. MarketBeat recorded 15 mentions for Immunovant and 8 mentions for Agios Pharmaceuticals. Immunovant's average media sentiment score of 0.45 beat Agios Pharmaceuticals' score of -0.01 indicating that Immunovant is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Agios Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Immunovant 4 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media refer more to IOVA or AGIO?

In the previous week, Agios Pharmaceuticals had 1 more articles in the media than Iovance Biotherapeutics. MarketBeat recorded 8 mentions for Agios Pharmaceuticals and 7 mentions for Iovance Biotherapeutics. Iovance Biotherapeutics' average media sentiment score of 0.56 beat Agios Pharmaceuticals' score of -0.01 indicating that Iovance Biotherapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Iovance Biotherapeutics 2 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Agios Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Agios Pharmaceuticals (AGIO) Competitors

$30.87 +0.66 (+2.18%)

As of 02:10 PM Eastern

Compare

AGIO vs. IONS, ALKS, GRAL, IMVT, and IOVA

Should you buy Agios Pharmaceuticals stock or one of its competitors? Agios Pharmaceuticals's main competitors and comparable companies include Ionis Pharmaceuticals (IONS), Alkermes (ALKS), GRAIL (GRAL), Immunovant (IMVT), and Iovance Biotherapeutics (IOVA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Agios Pharmaceuticals compare to Ionis Pharmaceuticals?

Ionis Pharmaceuticals (NASDAQ:IONS) and Agios Pharmaceuticals (NASDAQ:AGIO) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, media sentiment, analyst recommendations, risk, dividends and valuation.

In the previous week, Agios Pharmaceuticals had 2 more articles in the media than Ionis Pharmaceuticals. MarketBeat recorded 8 mentions for Agios Pharmaceuticals and 6 mentions for Ionis Pharmaceuticals. Ionis Pharmaceuticals' average media sentiment score of 0.47 beat Agios Pharmaceuticals' score of -0.01 indicating that Ionis Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ionis Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Agios Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

93.9% of Ionis Pharmaceuticals shares are held by institutional investors. 1.8% of Ionis Pharmaceuticals shares are held by company insiders. Comparatively, 5.4% of Agios Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Ionis Pharmaceuticals has a beta of 0.38, meaning that its stock price is 62% less volatile than the broader market. Comparatively, Agios Pharmaceuticals has a beta of 0.63, meaning that its stock price is 37% less volatile than the broader market.

Ionis Pharmaceuticals presently has a consensus target price of $89.20, suggesting a potential upside of 110.48%. Agios Pharmaceuticals has a consensus target price of $41.50, suggesting a potential upside of 37.37%. Given Ionis Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts plainly believe Ionis Pharmaceuticals is more favorable than Agios Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ionis Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	17 Buy rating(s)	0 Strong Buy rating(s)	2.73
Agios Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.55

Ionis Pharmaceuticals has higher revenue and earnings than Agios Pharmaceuticals. Ionis Pharmaceuticals is trading at a lower price-to-earnings ratio than Agios Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ionis Pharmaceuticals	$944M	7.46	-$381.39M	-$3.46	N/A
Agios Pharmaceuticals	$54.03M	33.38	-$412.78M	-$7.01	N/A

Ionis Pharmaceuticals has a net margin of -64.76% compared to Agios Pharmaceuticals' net margin of -418.24%. Agios Pharmaceuticals' return on equity of -35.67% beat Ionis Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ionis Pharmaceuticals	-64.76%	-111.08%	-17.41%
Agios Pharmaceuticals	-418.24%	-35.67%	-33.06%

Summary

Ionis Pharmaceuticals beats Agios Pharmaceuticals on 10 of the 17 factors compared between the two stocks.

How does Agios Pharmaceuticals compare to Alkermes?

Agios Pharmaceuticals (NASDAQ:AGIO) and Alkermes (NASDAQ:ALKS) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, media sentiment, risk, dividends, profitability, analyst recommendations, institutional ownership and valuation.

Agios Pharmaceuticals currently has a consensus target price of $41.50, indicating a potential upside of 37.37%. Alkermes has a consensus target price of $54.47, indicating a potential upside of 37.10%. Given Agios Pharmaceuticals' higher probable upside, research analysts clearly believe Agios Pharmaceuticals is more favorable than Alkermes.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Agios Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.55
Alkermes	1 Sell rating(s)	5 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	2.74

95.2% of Alkermes shares are owned by institutional investors. 5.4% of Agios Pharmaceuticals shares are owned by company insiders. Comparatively, 4.6% of Alkermes shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Agios Pharmaceuticals had 4 more articles in the media than Alkermes. MarketBeat recorded 8 mentions for Agios Pharmaceuticals and 4 mentions for Alkermes. Alkermes' average media sentiment score of 0.35 beat Agios Pharmaceuticals' score of -0.01 indicating that Alkermes is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Agios Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Alkermes	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Agios Pharmaceuticals has a beta of 0.63, indicating that its share price is 37% less volatile than the broader market. Comparatively, Alkermes has a beta of 0.32, indicating that its share price is 68% less volatile than the broader market.

Alkermes has higher revenue and earnings than Agios Pharmaceuticals. Agios Pharmaceuticals is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Agios Pharmaceuticals	$54.03M	33.38	-$412.78M	-$7.01	N/A
Alkermes	$1.48B	4.52	$241.66M	$0.38	104.55

Alkermes has a net margin of 3.96% compared to Agios Pharmaceuticals' net margin of -418.24%. Alkermes' return on equity of 4.15% beat Agios Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Agios Pharmaceuticals	-418.24%	-35.67%	-33.06%
Alkermes	3.96%	4.15%	2.19%

Summary

Alkermes beats Agios Pharmaceuticals on 12 of the 17 factors compared between the two stocks.

How does Agios Pharmaceuticals compare to GRAIL?

GRAIL (NASDAQ:GRAL) and Agios Pharmaceuticals (NASDAQ:AGIO) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, earnings, institutional ownership, profitability, valuation, dividends and risk.

GRAIL has higher revenue and earnings than Agios Pharmaceuticals. GRAIL is trading at a lower price-to-earnings ratio than Agios Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GRAIL	$147.17M	42.60	-$408.35M	-$9.75	N/A
Agios Pharmaceuticals	$54.03M	33.38	-$412.78M	-$7.01	N/A

GRAIL currently has a consensus target price of $119.80, indicating a potential downside of 14.64%. Agios Pharmaceuticals has a consensus target price of $41.50, indicating a potential upside of 37.37%. Given Agios Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Agios Pharmaceuticals is more favorable than GRAIL.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GRAIL	1 Sell rating(s)	6 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.33
Agios Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.55

GRAIL has a beta of 2.83, suggesting that its share price is 183% more volatile than the broader market. Comparatively, Agios Pharmaceuticals has a beta of 0.63, suggesting that its share price is 37% less volatile than the broader market.

In the previous week, GRAIL had 10 more articles in the media than Agios Pharmaceuticals. MarketBeat recorded 18 mentions for GRAIL and 8 mentions for Agios Pharmaceuticals. GRAIL's average media sentiment score of 0.46 beat Agios Pharmaceuticals' score of -0.01 indicating that GRAIL is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GRAIL	5 Very Positive mention(s)	4 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Agios Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

GRAIL has a net margin of -236.95% compared to Agios Pharmaceuticals' net margin of -418.24%. GRAIL's return on equity of -15.88% beat Agios Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GRAIL	-236.95%	-15.88%	-14.02%
Agios Pharmaceuticals	-418.24%	-35.67%	-33.06%

Summary

GRAIL beats Agios Pharmaceuticals on 9 of the 13 factors compared between the two stocks.

How does Agios Pharmaceuticals compare to Immunovant?

Agios Pharmaceuticals (NASDAQ:AGIO) and Immunovant (NASDAQ:IMVT) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, dividends, earnings, valuation, institutional ownership, risk, profitability and analyst recommendations.

47.1% of Immunovant shares are owned by institutional investors. 5.4% of Agios Pharmaceuticals shares are owned by company insiders. Comparatively, 1.9% of Immunovant shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Agios Pharmaceuticals has higher revenue and earnings than Immunovant. Immunovant is trading at a lower price-to-earnings ratio than Agios Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Agios Pharmaceuticals	$54.03M	33.38	-$412.78M	-$7.01	N/A
Immunovant	N/A	N/A	-$505.61M	-$2.82	N/A

In the previous week, Immunovant had 7 more articles in the media than Agios Pharmaceuticals. MarketBeat recorded 15 mentions for Immunovant and 8 mentions for Agios Pharmaceuticals. Immunovant's average media sentiment score of 0.45 beat Agios Pharmaceuticals' score of -0.01 indicating that Immunovant is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Agios Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Immunovant	4 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Agios Pharmaceuticals has a beta of 0.63, meaning that its stock price is 37% less volatile than the broader market. Comparatively, Immunovant has a beta of 0.84, meaning that its stock price is 16% less volatile than the broader market.

Agios Pharmaceuticals currently has a consensus target price of $41.50, indicating a potential upside of 37.37%. Immunovant has a consensus target price of $44.00, indicating a potential upside of 53.26%. Given Immunovant's stronger consensus rating and higher possible upside, analysts plainly believe Immunovant is more favorable than Agios Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Agios Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.55
Immunovant	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.58

Immunovant has a net margin of 0.00% compared to Agios Pharmaceuticals' net margin of -418.24%. Agios Pharmaceuticals' return on equity of -35.67% beat Immunovant's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Agios Pharmaceuticals	-418.24%	-35.67%	-33.06%
Immunovant	N/A	-69.59%	-62.49%

Summary

Immunovant beats Agios Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

How does Agios Pharmaceuticals compare to Iovance Biotherapeutics?

Iovance Biotherapeutics (NASDAQ:IOVA) and Agios Pharmaceuticals (NASDAQ:AGIO) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, valuation, risk, dividends, earnings, analyst recommendations, institutional ownership and media sentiment.

Iovance Biotherapeutics has a beta of 0.76, meaning that its stock price is 24% less volatile than the broader market. Comparatively, Agios Pharmaceuticals has a beta of 0.63, meaning that its stock price is 37% less volatile than the broader market.

Iovance Biotherapeutics has higher revenue and earnings than Agios Pharmaceuticals. Iovance Biotherapeutics is trading at a lower price-to-earnings ratio than Agios Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Iovance Biotherapeutics	$263.50M	24.93	-$390.98M	-$0.73	N/A
Agios Pharmaceuticals	$54.03M	33.38	-$412.78M	-$7.01	N/A

77.0% of Iovance Biotherapeutics shares are held by institutional investors. 7.8% of Iovance Biotherapeutics shares are held by company insiders. Comparatively, 5.4% of Agios Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Agios Pharmaceuticals had 1 more articles in the media than Iovance Biotherapeutics. MarketBeat recorded 8 mentions for Agios Pharmaceuticals and 7 mentions for Iovance Biotherapeutics. Iovance Biotherapeutics' average media sentiment score of 0.56 beat Agios Pharmaceuticals' score of -0.01 indicating that Iovance Biotherapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Iovance Biotherapeutics	2 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Agios Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Iovance Biotherapeutics presently has a consensus price target of $13.20, indicating a potential downside of 8.97%. Agios Pharmaceuticals has a consensus price target of $41.50, indicating a potential upside of 37.37%. Given Agios Pharmaceuticals' higher possible upside, analysts clearly believe Agios Pharmaceuticals is more favorable than Iovance Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Iovance Biotherapeutics	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.62
Agios Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.55

Iovance Biotherapeutics has a net margin of -89.11% compared to Agios Pharmaceuticals' net margin of -418.24%. Agios Pharmaceuticals' return on equity of -35.67% beat Iovance Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Iovance Biotherapeutics	-89.11%	-40.51%	-31.65%
Agios Pharmaceuticals	-418.24%	-35.67%	-33.06%

Summary

Iovance Biotherapeutics beats Agios Pharmaceuticals on 11 of the 17 factors compared between the two stocks.

Get Agios Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AGIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AGIO vs. The Competition

Export

Metric	Agios Pharmaceuticals	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.83B	$3.89B	$7.27B	$12.97B
Dividend Yield	N/A	3.65%	2.51%	22.89%
P/E Ratio	-4.37	12.96	275.40	25.37
Price / Sales	33.85	1,150.23	562.29	78.82
Price / Cash	N/A	118.50	77.16	53.04
Price / Book	1.50	16.59	10.55	5.95
Net Income	-$412.78M	-$22.65M	$3.50B	$380.75M
7 Day Performance	-3.64%	-6.11%	-3.92%	-3.96%
1 Month Performance	-7.79%	-13.89%	-8.30%	-6.81%
1 Year Performance	-23.87%	6.58%	2.35%	-4.58%

Agios Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AGIO Agios Pharmaceuticals	3.0228 of 5 stars	$30.87 +2.2%	$41.50 +34.4%	-26.2%	$1.85B	$54.03M	N/A	540
IONS Ionis Pharmaceuticals	3.2557 of 5 stars	$43.50 -0.1%	$89.20 +105.1%	-40.0%	$7.24B	$944M	N/A	1,402
ALKS Alkermes	3.1987 of 5 stars	$42.76 +2.4%	$54.47 +27.4%	+23.5%	$7.00B	$1.48B	112.53	2,050
GRAL GRAIL	1.4329 of 5 stars	$154.08 +7.6%	$102.70 -33.3%	+99.2%	$6.88B	$165.26M	N/A	910	Analyst Forecast
IMVT Immunovant	2.4556 of 5 stars	$33.25 -1.1%	$44.00 +32.3%	+65.5%	$6.87B	N/A	N/A	315

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AGIO) was last updated on 10/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Agios Pharmaceuticals (AGIO) Competitors

AGIO vs. IONS, ALKS, GRAL, IMVT, and IOVA

How does Agios Pharmaceuticals compare to Ionis Pharmaceuticals?

Summary

How does Agios Pharmaceuticals compare to Alkermes?

Summary

How does Agios Pharmaceuticals compare to GRAIL?

Summary

How does Agios Pharmaceuticals compare to Immunovant?

Summary

How does Agios Pharmaceuticals compare to Iovance Biotherapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AGIO vs. The Competition

Agios Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Agios Pharmaceuticals (AGIO) Competitors

AGIO vs. IONS, ALKS, GRAL, IMVT, and IOVA

How does Agios Pharmaceuticals compare to Ionis Pharmaceuticals?

Does the media prefer IONS or AGIO?

Do institutionals and insiders have more ownership in IONS or AGIO?

Which has more volatility & risk, IONS or AGIO?

Do analysts recommend IONS or AGIO?

Which has preferable earnings and valuation, IONS or AGIO?

Is IONS or AGIO more profitable?

Summary

How does Agios Pharmaceuticals compare to Alkermes?

Do analysts rate AGIO or ALKS?

Do insiders & institutionals hold more shares of AGIO or ALKS?

Does the media refer more to AGIO or ALKS?

Which has more volatility & risk, AGIO or ALKS?

Which has higher earnings & valuation, AGIO or ALKS?

Is AGIO or ALKS more profitable?

Summary

How does Agios Pharmaceuticals compare to GRAIL?

Which has higher valuation and earnings, GRAL or AGIO?

Do analysts rate GRAL or AGIO?

Which has more risk and volatility, GRAL or AGIO?

Does the media refer more to GRAL or AGIO?

Is GRAL or AGIO more profitable?

Summary

How does Agios Pharmaceuticals compare to Immunovant?

Do institutionals and insiders believe in AGIO or IMVT?

Which has stronger earnings and valuation, AGIO or IMVT?

Does the media favor AGIO or IMVT?

Which has more risk and volatility, AGIO or IMVT?

Do analysts recommend AGIO or IMVT?

Is AGIO or IMVT more profitable?

Summary

How does Agios Pharmaceuticals compare to Iovance Biotherapeutics?

Which has more volatility and risk, IOVA or AGIO?

Which has better valuation and earnings, IOVA or AGIO?

Do insiders & institutionals believe in IOVA or AGIO?

Does the media refer more to IOVA or AGIO?

Do analysts prefer IOVA or AGIO?

Is IOVA or AGIO more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AGIO vs. The Competition

Agios Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools